Cargando…

Radiotherapy plus temozolomide in elderly patients with glioblastoma: a “real-life” report

BACKGROUND: The optimization of the management for elderly glioblastoma patients is crucial given the demographics of aging in many countries. We report the outcomes for a “real-life” patient cohort (i.e. unselected) comprising consecutive glioblastoma patients aged 70 years or more, treated with di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biau, J., Chautard, E., De Schlichting, E., Dupic, G., Pereira, B., Fogli, A., Müller-Barthélémy, M., Dalloz, P., Khalil, T., Dillies, A. F., Durando, X., Godfraind, C., Verrelle, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719937/ https://www.ncbi.nlm.nih.gov/pubmed/29212499 http://dx.doi.org/10.1186/s13014-017-0929-2

Ejemplares similares

Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-Analysis
por: Yin, An-an, et al.
Publicado: (2013)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Second course of stereotactic radiosurgery for locally recurrent brain metastases: Safety and efficacy
por: Moreau, Juliette, et al.
Publicado: (2018)

Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial
por: Ginzac, Angeline, et al.
Publicado: (2021)

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Predictive biomarkers of resistance to hypofractionated radiotherapy in high grade glioma
por: Biau, Julian, et al.
Publicado: (2017)

Local control and radionecrosis of brain metastases from non-small-cell lung cancer treated by hypofractionated stereotactic radiotherapy: Evaluation of predictive factors
por: Leyrat, Brice, et al.
Publicado: (2022)

DTI Abnormalities Related to Glioblastoma: A Prospective Comparative Study with Metastasis and Healthy Subjects
por: El Ouadih, Youssef, et al.
Publicado: (2022)

Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting
por: Biau, Julian, et al.
Publicado: (2019)

Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results
por: Oike, Takahiro, et al.
Publicado: (2013)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma
por: Metcalfe, Evrim, et al.
Publicado: (2016)

Transcriptional alterations in glioma result primarily from DNA methylation–independent mechanisms
por: Court, Franck, et al.
Publicado: (2019)

Fractionated stereotactic radiotherapy of benign skull-base tumors: a dosimetric comparison of volumetric modulated arc therapy with Rapidarc® versus non-coplanar dynamic arcs
por: Martin, Fanny, et al.
Publicado: (2016)

Interleukin-6 gene amplification and shortened survival in glioblastoma patients
por: Tchirkov, A, et al.
Publicado: (2007)

Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma: Efficacy and Protein Biomarkers of Resistance in Preclinical Models
por: Biau, Julian, et al.
Publicado: (2019)

A Preclinical Study Combining the DNA Repair Inhibitor Dbait with Radiotherapy for the Treatment of Melanoma()
por: Biau, Julian, et al.
Publicado: (2014)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
por: Nguyen, Ludovic T., et al.
Publicado: (2013)

Toxicity and Outcome of Radiotherapy with Concomitant and Adjuvant Temozolomide in Elderly Patients with Glioblastoma: A Retrospective Study
por: SAITO, Kuniaki, et al.
Publicado: (2014)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)
por: Thivat, Emilie, et al.
Publicado: (2023)

Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review
por: Su, Jiahao, et al.
Publicado: (2016)

Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
por: She, Lei, et al.
Publicado: (2022)

Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study
por: Wang, Yong, et al.
Publicado: (2019)

Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study
por: Wei, Kuo-Chen, et al.
Publicado: (2021)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Short Interval Infield Sarcoma Development following Resection of Glioblastoma and Adjuvant Radiotherapy and Temozolomide
por: Alotaibi, Fahad E., et al.
Publicado: (2013)

Global Conservation of Protein Status between Cell Lines and Xenografts()
por: Biau, Julian, et al.
Publicado: (2016)

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
por: Reyes‐Botero, Germán, et al.
Publicado: (2018)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)

Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials
por: Du, Chigang, et al.
Publicado: (2016)

Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide
por: Topkan, Erkan, et al.
Publicado: (2020)

Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
por: Omuro, Antonio, et al.
Publicado: (2022)

Stereotactic Radiosurgery for Vestibular Schwannomas: Reducing Toxicity With 11 Gy as the Marginal Prescribed Dose
por: Dupic, Guillaume, et al.
Publicado: (2020)

Assessment of the risk factors for impending fractures following radiotherapy for long bone metastases using CT scan-based virtual simulation: a retrospective study
por: Tatar, Zuzana, et al.
Publicado: (2014)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings
por: Hilverda, Karen, et al.
Publicado: (2009)

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
por: Fulton, Ben, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_53mn49dnp90q89gu41hkhso2tl